证券代码：002772 证券简称：众兴菌业 公告编号：2025-045 天水众兴菌业科技股份有限公司 第五届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 天水众兴菌业科技股份有限公司（以下简称"公司"）第五届监事会第九次 会议于 2025 年 08 月 15 日在公司会议室以通讯方式召开。召开本次会议的通知 已于 2025 年 08 月 04 日以电子邮件方式送达各位监事。 本次会议由监事会主席张天荣先生主持，会议应出席监事 3 名，实际出席 3 名。会议召开程序符合《公司法》和《公司章程》等的有关规定。 二、监事会会议审议情况 经与会监事认真审议，本次会议以记名投票表决方式表决通过了以下议案： （一）审议通过了《关于公司<2025 年半年度报告全文及摘要>的议案》 监事会认为：董事会编制和审核公司《2025 年半年度报告》的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。同意通过该报告并 签署了书面确认意见。 表决情况 ...

天水众兴菌业科技股份有限公司 第五届董事会第十四次会议决议公告 证券代码：002772 证券简称：众兴菌业 公告编号：2025-044 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 天水众兴菌业科技股份有限公司（以下简称"公司"）第五届董事会第十四 次会议于 2025 年 08 月 15 日在公司会议室以现场结合通讯方式召开。本次会议 由公司董事长高博书先生主持，会议通知已于 2025 年 08 月 04 日以电子邮件方 式送达给全体董事和高级管理人员。本次会议应出席董事 9 人，实际出席董事 9 人（其中董事邵小军先生、独立董事党琳女士以通讯表决方式出席），公司监事、 高级管理人员列席了本次会议。 本次会议的召开程序符合《公司法》等法律法规和《公司章程》等的有关规 定。 二、董事会会议审议情况 经与会董事认真审议，本次会议以记名投票表决方式表决通过了以下议案： （一）审议通过了《关于公司<2025 年半年度报告全文及摘要>的议案》 表决情况：9 票同意、0 票反对、0 票弃权、0 票回避 表决结果：通过 本议案在提交董事会审议前，已 ...

天水众兴菌业科技股份有限公司 2025 年半年度报告全文 天水众兴菌业科技股份有限公司 2025 年半年度报告 2025 年 08 月 1 天水众兴菌业科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人刘亮、主管会计工作负责人李敏及会计机构负责人（会计主 管人员）何文科声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及未来计划等前瞻性陈述均不构成公司对广大投资者的实质承诺， 投资者及相关人士均应对此保持足够的风险认识，并应当理解计划、预测与 承诺之间的差异，敬请投资者注意投资风险，理性投资。 公司需遵守《深圳证券交易所上市公司自律监管指引第 3 号——行业信 息披露》中的"种业、种植业务"的披露要求 公司在本报告第三节"管理层讨论与分析"之"十、公司面临的风险和应对 措施"详细描述了公司经营中可能存在的风险及公司应对措施，敬请广大投资 者关注并注意投资风险。 ...

Market Performance - The planting industry sector increased by 0.59% on August 5, with Shennong Seed Industry leading the gains [1] - The Shanghai Composite Index closed at 3617.6, up 0.96%, while the Shenzhen Component Index closed at 11106.96, up 0.59% [1] Stock Performance - Key stocks in the planting industry and their performance include: - Shennong Seed Industry (300189): Closed at 4.84, up 2.76% with a trading volume of 1.3433 million shares and a turnover of 647.1 million [1] - Honghui Fruits and Vegetables (603336): Closed at 7.56, up 2.16% with a trading volume of 233,600 shares and a turnover of 175 million [1] - Qiu Le Shen V (831087): Closed at 18.50, up 1.37% with a trading volume of 44,300 shares and a turnover of 81.8 million [1] - Other notable stocks include Zhongxing Junye (002772), Boyuan Technology (600883), and Xin Sai Co., Ltd. (600540) with respective gains [1] Capital Flow - The planting industry sector saw a net inflow of 28.2654 million from institutional investors, while retail investors experienced a net outflow of 29.8697 million [1] - Notable capital flows for specific stocks include: - Nuofushin (002215): Net inflow of 29.6542 million from institutional investors, but a net outflow of 25.6975 million from retail investors [2] - Shennong Seed Industry (300189): Net inflow of 27.3554 million from institutional investors, with a net outflow of 19.3483 million from retail investors [2] - Other stocks like Jingyin Gaoke (300087) and Su Keng Agricultural Development (601952) also showed similar trends in capital flow [2]

Group 1 - The core viewpoint of the news is that Zhongxing Junye (002772.SZ) expects a significant increase in its net profit for the first half of 2025, with a projected growth of 86.57% to 137.46% year-on-year [1] - The company anticipates a net profit attributable to shareholders of 55 million to 70 million yuan for the first half of 2025, and a non-net profit of 42 million to 57 million yuan, indicating a year-on-year increase of 105.39% to 178.74% [1] - The reasons for the performance change include stable price increases for its Agaricus bisporus products, increased investment income from its joint venture, and a rise in investment income and fair value changes from financial products by approximately 8 million yuan [1] Group 2 - In 2024, Zhongxing Junye reported an operating income of 1.935 billion yuan, a slight increase of 0.21% year-on-year, while the net profit attributable to shareholders decreased by 19.77% to 128 million yuan [3] - The non-net profit for 2024 was reported at 91.77 million yuan, reflecting a decline of 30.07% year-on-year [3] - The company’s vice chairman and vice general manager, Tao Chunhui, is noted for being young and accomplished, having held various positions within the company since 2020 [3]

证券代码：002772 证券简称：众兴菌业 公告编号：2025-043 天水众兴菌业科技股份有限公司 关于使用部分闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 天水众兴菌业科技股份有限公司（以下简称"公司"）于 2025 年 03 月 21 日召开第五届董事会第十次会议及第五届监事会第六次会议审议通过了《关于使 用部分闲置自有资金进行委托理财的议案》，同意公司（包括控股子公司，下同） 在确保不影响正常运营和资金安全的前提下，使用不超过 60,000 万元（含 60,000 万元，下同）闲置自有资金（含截至董事会召开日未赎回的委托理财产品金额， 下同）进行委托理财，额度使用期限自董事会审议通过之日起 12 个月内。在额 度和有效期内资金可以滚动使用，期限内任一时点的委托理财金额（含前述投资 的收益进行再投资的相关金额）不得超过 60,000 万元。公司董事会授权公司经 营管理层行使投资决策权并签署相关文件。《关于使用部分闲置自有资金进行委 托理财的公告》（公告编号：2025-016）详见 2025 年 03 月 22 日公司 ...

Core Viewpoint - The company, Zhongxing Junye, is experiencing a significant increase in profitability, with a projected net profit for the first half of 2025 expected to grow by 86.57% to 137.46% compared to the same period last year [1][2]. Financial Performance - In 2024, the company achieved a revenue of 19.35 billion yuan, a slight increase of 0.21% year-on-year, but net profit decreased by 19.77% to 1.28 billion yuan [2]. - The sales volume of edible mushrooms reached 359,000 tons in 2024, marking a 9.01% increase year-on-year [2]. - For the first quarter of 2025, the company reported a revenue of 4.73 billion yuan and a net profit of 482 million yuan, reflecting a year-on-year growth of 38.72% [2]. Product and Market Strategy - The company focuses on a multi-variety development strategy, primarily cultivating enoki mushrooms and button mushrooms, and has established production bases across several provinces in China [2][4]. - The sales price of button mushrooms has been stable, contributing to improved single product performance [3]. Investment and Expansion Plans - The company has been actively investing in expansion projects, including a 50 million yuan investment to establish a new company for cultivating Cordyceps [4]. - Plans include a 550 million yuan investment to build a mushroom industry park to enhance market share in button mushrooms [4]. - The company aims to diversify its business by investing in projects related to the cultivation of rare medicinal mushrooms [4][5].

Core Viewpoint - Zhongxing Junye (002772.SZ) expects a significant increase in net profit for the first half of 2025, projecting a growth of 86.57% to 137.46% compared to the same period last year [1] Financial Performance - The estimated net profit attributable to shareholders is between 55 million and 70 million yuan [1] - The sales price of Agaricus bisporus products has remained stable with an upward trend, contributing to improved single product performance [1] - Investment income from joint ventures has increased year-on-year [1] - Investment income from financial products and changes in fair value have increased by approximately 8 million yuan year-on-year [1] - Financial expenses have decreased compared to the previous year [1]

[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates a significant year-on-year increase in its 2025 first-half net profit, with attributable net profit projected between 55 million and 70 million yuan Performance Forecast Summary | Item | Current Period | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | **Profit: 55.00 Million Yuan—70.00 Million Yuan** | Profit: 29.4788 Million Yuan | | Growth Rate | **Year-on-year increase: 86.57% —137.46%** | - | | **Net Profit After Deducting Non-recurring Gains and Losses** | **Profit: 42.00 Million Yuan—57.00 Million Yuan** | Profit: 20.4493 Million Yuan | | Growth Rate | **Year-on-year increase: 105.39% —178.74%** | - | | **Basic Earnings Per Share** | **Profit: 0.1466 Yuan/share—0.1866 Yuan/share** | Profit: 0.0750 Yuan/share | - The company characterizes the current period's performance forecast as "year-on-year growth"[3](index=3&type=chunk) [Communication with Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The financial data presented in this performance forecast represents preliminary internal estimates, pending pre-audit by an independent accounting firm - The financial data in this performance forecast is a preliminary estimate by the company's finance department and has not been pre-audited by an accounting firm[3](index=3&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) Current period performance growth is primarily attributed to stable button mushroom prices, increased joint venture investment income, higher wealth management gains, and reduced financial expenses - Key drivers of performance growth include: - Stable to rising sales prices for button mushrooms, enhancing single-product operating performance - Increased investment income from the joint venture Tianshui Jinxing Biotechnology Co., Ltd. year-on-year - Approximately **8 million yuan** increase in investment income and fair value changes from wealth management products year-on-year - A year-on-year decrease in financial expenses[4](index=4&type=chunk) [Risk Warning and Other Related Disclosures](index=1&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA%E5%8F%8A%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company cautions investors that this preliminary, unaudited performance forecast is subject to change, with final figures to be confirmed in the 2025 semi-annual report - The company emphasizes that this performance forecast is a preliminary estimate by the finance department, unaudited, with final data subject to the 2025 semi-annual report, and advises investors to be aware of investment risks[5](index=5&type=chunk)[6](index=6&type=chunk)

Overview - The industrialized production of edible mushrooms has rapidly developed due to advancements in production technology, equipment manufacturing, and market demand growth. In 2023, China's industrialized production of edible mushrooms reached 4.092 million tons, a year-on-year increase of 43.26%, with a production rate of 9.4%. It is projected that in 2024, production will exceed 4.2 million tons, with enoki mushrooms and king oyster mushrooms accounting for over 60% of the total [1][10]. Market Policies - The Chinese government has issued several policies to support the development of the edible mushroom industry, including the "Rural Construction Action Implementation Plan" and various opinions aimed at promoting rural revitalization and enhancing the agricultural supply chain. These policies create a favorable environment for the industrialized production of edible mushrooms [5][7]. Industry Chain - The upstream of the industrialized mushroom production industry includes mushroom strains, substrate materials (such as wood chips and corn cobs), cultivation containers, and production equipment. The midstream involves the actual production of edible mushrooms, while the downstream consists of the consumer market, including processing, catering, and household consumption [8]. Competitive Landscape - As of November 2024, there are 311 industrialized mushroom production enterprises in China, a decrease from 316 in 2023. The leading production varieties include king oyster mushrooms and enoki mushrooms. The market is characterized by a "two strong, many strong" structure, with 21 companies producing over 100 tons per day, including Shanghai Xuerong Biotechnology Co., Ltd. and Tianshui Zhongxing Mushroom Industry Technology Co., Ltd. [12][14]. Company Analysis - Shanghai Xuerong Biotechnology Co., Ltd. focuses on modern biological technology and industrialized production methods, achieving a revenue of 2.162 billion yuan in 2024, with 98.66% from mushroom business [17]. - Tianshui Zhongxing Mushroom Industry Technology Co., Ltd. reported a revenue of 1.935 billion yuan in 2024, with a significant portion from the sales of common mushroom varieties [19]. Development Trends - The future of the industry will see a diversification in production, with companies shifting towards rare and high-end mushroom varieties to meet consumer demand. Additionally, there is a trend of expanding into overseas markets, with companies like Shanghai Fengke Biotechnology establishing bases in countries such as Singapore and Germany [21].